Clenbuterol

( DrugBank: Clenbuterol / KEGG DRUG: Clenbuterol )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
1	球脊髄性筋萎縮症	1
2	筋萎縮性側索硬化症	1

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2
256	筋型糖原病	1

1. 球脊髄性筋萎縮症

臨床試験数 : 18 / 薬物数 : 15 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 17

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-022558-18-IT (EUCTR)	11/10/2010	28/09/2012	A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).	A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).	spinal and bulbar muscular atrophy (SBMA) MedDRA version: 15.0;Level: HLGT;Classification code 10029 ...	Trade Name: MONORES*30CPR 20MCG INN or Proposed INN: Clenbuterol	AZIENDA OSPEDALIERA DI PADOVA	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes			Italy

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04245709 (ClinicalTrials.gov)	February 10, 2020	26/1/2020	Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis	A Clinical Investigation of the Safety and Efficacy of Clenbuterolon Motor Function in Individuals W ...	Amyotrophic Lateral Sclerosis	Drug: Clenbuterol	Dwight Koeberl, M.D., Ph.D.	NULL	Completed	18 Years	N/A	All	25	Phase 2	United States

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-003796-17-GB (EUCTR)	22/10/2020	01/09/2020	A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.	An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cogni ...	Patients with Mild Cognitive Impairment or Parkinson’s Disease MedDRA version: 21.1;Level: LLT;Class ...	Trade Name: Spiropent Product Name: ClenbuterolHCl Product Code: CST-103 INN or Proposed INN: CLENBUTER ...	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 2	United Kingdom
2	EUCTR2020-006067-28-BE (EUCTR)		18/11/2021	A study to investigate if CST-103 and CST-107 has an effect on the brain in patients with progressiv ...	A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Ef ...	Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Deme ...	Trade Name: Spiropent Product Name: Spiropent Product Code: CST-103 INN or Proposed INN: ClenbuterolHyd ...	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Belgium;Australia;United Kingdom;New Zealand

臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01942590 (ClinicalTrials.gov)	September 2013	11/9/2013	Safety and Efficacy of Clenbuterolin Individuals With Late-onset Pompe Disease and Receiving Enzyme ...	A Clinical Investigation of the Safety and Efficacy of Clenbuterolon Motor Function in Individuals W ...	Pompe Disease	Drug: Clenbuterol;Drug: Placebo	Dwight Koeberl, M.D., Ph.D.	NULL	Completed	18 Years	N/A	All	17	Phase 1/Phase 2	United States